Literature DB >> 23295929

MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.

Valentina Salas1, F Javier Pastor, Deanna A Sutton, Enrique Calvo, Emilio Mayayo, Annette W Fothergill, Michael G Rinaldi, Josep Guarro.   

Abstract

We evaluated the efficacy of voriconazole against nine strains of Aspergillus terreus with different MICs (0.12 to 4 μg/ml) by using a murine model. Markers of efficacy included survival, tissue burden, galactomannan antigenemia, and drug serum levels. Voriconazole was especially effective in prolonging survival and reducing the fungal load in infections by strains that showed MICs that were less than or equal to the epidemiological cutoff value (1 μg/ml). In vitro data might be useful for predicting the outcome of A. terreus infections.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23295929      PMCID： PMC3591889          DOI： 10.1128/AAC.01436-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 2.  Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi.

Authors:  Josep Guarro
Journal:  J Antimicrob Chemother       Date:  2011-04-14       Impact factor: 5.790

3.  Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.

Authors:  Edward Sionov; Sonia Mendlovic; Esther Segal
Journal:  J Antimicrob Chemother       Date:  2005-07-08       Impact factor: 5.790

4.  Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.

Authors:  P H Chandrasekar; J Cutright; E Manavathu
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

5.  Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.

Authors:  Cornelia Lass-Flörl; Katharina Griff; Astrid Mayr; Andreas Petzer; Günter Gastl; Hugo Bonatti; Martin Freund; Gabriele Kropshofer; Manfred P Dierich; David Nachbaur
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

6.  Organism-dependent fungicidal activities of azoles.

Authors:  E K Manavathu; J L Cutright; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans.

Authors:  M Mar Rodríguez; Enrique Calvo; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.

Authors:  J Majithiya; A Sharp; A Parmar; D W Denning; P A Warn
Journal:  J Antimicrob Chemother       Date:  2008-11-13       Impact factor: 5.790

9.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

10.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Authors:  Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Journal:  J Antimicrob Chemother       Date:  2006-10-27       Impact factor: 5.758
View more
  4 in total

Review 1.  Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

Authors:  Laura L Kovanda; Amit V Desai; William W Hope
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-08       Impact factor: 2.745

Review 2.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

3.  Molecular epidemiology and in-vitro antifungal susceptibility of Aspergillus terreus species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typing.

Authors:  Shallu Kathuria; Cheshta Sharma; Pradeep Kumar Singh; Puneet Agarwal; Kshitij Agarwal; Ferry Hagen; Jacques F Meis; Anuradha Chowdhary
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 4.  Treatment of Infections Due to Aspergillus terreus Species Complex.

Authors:  Cornelia Lass-Flörl
Journal:  J Fungi (Basel)       Date:  2018-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.